Trial Profile
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Carboplatin
- Indications Ovarian cancer; Uterine cancer
- Focus Therapeutic Use
- 23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
- 25 Oct 2011 Additional lead trial center identified and company added in the association field as reported by ClinicalTrials.gov.
- 07 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov